Mylan Will Invest $1bn In India
The investment over the next 5-6 years will support Mylan's global supply chain
Generics giant Mylan, which has a large chunk of its manufacturing operations in India, has said it will invest $1bn over the next five to six years in the country, maintaining the spending pace the company has established over the last few years.
You may also be interested in...
Mylan will be merged into a new company with Pfizer’s Upjohn, closing the chapter on a generic drug powerhouse that will be remembered as much for scandal as success.
Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.